

Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3
4
5
6
7
8
9
10
11
12
13

Raman spectroscopy of oral tissues: correlation of spectral and biochemical markers

S.P. Singh¹, C. Murali Krishna^{1,*}

¹Chilakapati Lab, ACTREC, Kharghar, Navi Mumbai - 410210

14 *Corresponding author:

15 Dr. C. Murali Krishna

16 Scientific Officer 'F' and Principal Investigator

17 Chilakapati Lab

18 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

19 Tata Memorial Centre (TMC)

20 Sector '22', Kharghar

21 Navi Mumbai – 410210, INDIA

22 Telephone: +91-22-27405039

23 Email: mchilakapati@actrec.gov.in, pittu1043@gmail.com

24
25
26
27
28
29
30
31
32
33
34 **Keywords:** Raman spectroscopy, Oral cancer, Curve deconvolution, Biochemical correlation.

35 Abbreviations used: OSCC- Oral squamous cell carcinoma, FTIR-Fourier Transformed Infra

36 Red, RS- Raman Spectroscopy.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Both *ex vivo* and *in vivo* Raman spectroscopic studies carried out in oral cancer over the past decade have demonstrated that the spectra of normal tissues are rich in lipids and tumors have predominant protein features. However, in view of variability in Raman scattering cross section of biomolecules, it is pertinent to explore spectral features *viz a viz* biochemical composition in order to verify spectral markers as biochemical markers. Spectra of 20 pairs of normal and tumor oral tissues were acquired using fiberoptic probe coupled Raman-spectrometer. Intensity associated with lipid (1440 cm^{-1}) and protein (1450 and 1660 cm^{-1}) bands were computed and correlated with biochemical estimation for protein, lipid and phospholipid from the same tissues. The intensity of the lipid band was higher in normal tissues while that of the protein band was higher in tumors. Biochemical estimation yielded similar results *i.e.* high protein to lipid or phospholipid ratio in tumors with respect to normal tissues. These differences were found to be statistically significant. Findings of curve-deconvolution and biochemical estimation correlate well and suggest that spectral features are the hallmark of underlying biochemical tissue composition.

1. Introduction

Cancer is the second most common cause of morbidity and mortality in the world today, after cardiovascular disorders. Oral cancer is the eleventh most common cancer in the world, with two-thirds of oral cancers occurring in the developing countries^{1,2}. Oral cancers in India accounts for >30% of all cancers as in contrast to USA, where oral cavity cancer represents only ~3% of all malignancies. India tops in the prevalence of oral cancer in the world (accounts for one-third of the global oral cancer burden) and remains the most common cancer among the males and third in females. Tobacco (both smoking and chewing) is regarded as the major cause of oral cancer³⁻⁵.

Early detection and diagnosis is the best means to reduce morbidity due to oral cancer. Screening by visual examination of high risk population lacks accuracy, reproducibility and requires expertise and may be useful only for chronic smokers and alcoholics. A definitive diagnosis is made only after the histopathological examination of a tissue biopsy. However this approach suffers from some of the known limitations like subjectivity, sampling error and patient discomfort, and further it may not be practical for screening^{6,7}.

Optical diagnostic methods based on fluorescence, Raman and Fourier transform infrared spectroscopy are being projected as promising new technologies for improving screening and detection of malignancies in several organs^{8,9}. These methods are capable of providing biochemical information within a short time frame which can be used for online diagnosis. Among these, Raman spectroscopy with attributes such as negligible water interference, sharp spectral signatures and abundance of Raman active molecules in biological samples holds edge over other methods. Raman spectroscopic differentiation of normal and cancerous conditions of prostate, esophagus, skin, cervix, and other forms of cancer have already been reported in the literature¹⁰⁻¹⁸. Recent Raman spectroscopic studies, both *ex vivo* and *in vivo*, have demonstrated the efficacy in classifying normal, pre-cancerous and cancerous conditions of oral cavity¹⁹⁻³⁰. We have also shown that confounding factor such as cancer field effects and age associated changes in the clinically normal appearing mucosa can be identified²⁹⁻³⁰. *Ex vivo* and *in vivo* Raman spectroscopic studies, carried out over last decade have established that spectra of normal conditions have predominant lipid features while tumors are rich in proteins²¹⁻³⁰. Absence of a particular biomolecule in the spectra is suggestive of the fact that either they are not present in

1
2
3 sufficient quantity or they lack does not have strong enough Raman scattering cross section
4 (indicates the strength of the signal at unit concentration) to appreciably contribute to the
5 spectrum³¹. Therefore, in view of variability in Raman scattering cross section of biomolecules,
6 it is pertinent to explore Raman spectral features *viz a viz* biochemical composition in order to
7 prove spectral markers are indeed direct biochemical markers. Hence, in the present study, gross
8 spectral features and band intensity parameters derived from curve-deconvolution studies have
9 been correlated with biochemical estimations of same tissues and findings are discussed in the
10 manuscript.

17 **2. Material and Methods**

18
19 **2.1 Clinical samples:** The study was approved by the Institutional Ethics Committee, Tata
20 Memorial Centre, Mumbai, India. *Ex vivo* biopsies of buccal mucosa tissues (20 pairs of normal/
21 histopathologically confirmed tumor tissues) were obtained from the Biorepository, ACTREC.
22 Tumor refers to the tumor tissue obtained during surgical resection of tumor of buccal mucosa.
23 Normal refers to the normal buccal mucosa tissue adjacent to the tumor obtained during surgical
24 removal of margins. Two frozen sections, each of 5- μ m thickness cut longitudinally by orienting
25 epithelium and connective tissue in order, were used for histopathological certification. The
26 remaining tissue was placed on a CaF₂ window and used for recording Raman spectra.

27
28 **2.2 Raman spectroscopy:** Spectra from the *ex vivo* biopsies were acquired with a fiberoptic
29 probe (RPS 785/12-5, InPhotonics Inc., Downey St., USA) coupled HE-785 commercial Raman
30 spectrometer (Jobin-Yvon-Horiba, France). An elaborate description of the instrument is given
31 elsewhere²⁵⁻³⁰. Briefly, the instrument consists of a diode laser (PI-ECL-785-300-FC, Process
32 Instruments) of 785 nm wavelength as the excitation source, a high efficiency (HE-785,
33 HORIBA Jobin Yvon, France) spectrograph with fixed 950 gr/mm grating coupled with CCD
34 (CCD-1024X256-BIDD-SYN, Synapse) as the detection components. The probe consists of 105-
35 μ m excitation fiber and 200- μ m collection fiber (NA-0.40). As per specifications of
36 manufacturer of the Inphotonics probe, theoretical spot size is 105 μ m. The spectral resolution as
37 per manufacturer's (HORIBA Jobin Yvon, France) specification is ~ 4 cm⁻¹. Passively thawed
38 samples were placed on a CaF₂ window and spectra were acquired at different points with
39 spacing of ~ 1 -2 mm using XYZ precision stage. On an average, 8 spectra were acquired from
40 each tissue. Spectral acquisition parameters were: λ_{ex} -785nm, laser power-52 mW, integration
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 time-10 seconds and accumulations-5. These parameters were kept constant during all
4 measurements and tissues were kept moist with saline to prevent desiccation.

7 **2.3 Data analysis**

8
9 **2.3.1 Spectral pre-processing:** Raman spectra were corrected for CCD response with a NIST
10 certified SRM 2241 material followed by subtraction of the background signals from optical
11 elements. Spectra were baseline corrected by fitting 5th order polynomial function followed by
12 smoothing (Savitzky-Golay method and window size 3) and vector normalization. Mean or
13 average spectra were computed by averaging variations on the Y- axis, keeping the X- axis
14 constant.

15
16 **2.3.2 Curve deconvolution:** The pre-processed, baseline corrected spectra were resolved into
17 individual component bands using curve deconvolution technique, based on the original
18 algorithm of Levenberg-Marquardt ³²⁻³⁵. In this method, the sum of the squared differences
19 between observed and computed spectra are minimized to get the best fit. The spectral region
20 1200 to 1800 cm⁻¹ was used for the deconvolution analysis. Normal and tumor oral tissue spectra
21 were resolved into 8 and 9 bands, respectively. Each band is characterized by four parameters:
22 shape factor, peak position, peak intensity and full width at half maximum (FWHM). The shape
23 factor decides the band shape. In our deconvolution analysis, the Gaussian band led to the best
24 fit. In order to understand the relative distribution of biomolecules, we have also generated
25 scatter intensity plots by computing the area under each of the fitted bands (integrated intensity).

26
27 **2.3.3 Statistical analysis:** The data were expressed as mean \pm standard deviation (SD), and
28 statistical comparisons were performed by unpaired student's t-test. p value <0.05 was
29 considered statistically significant, p < 0.01 as highly significant and p < 0.001 as very highly
30 significant.

31 **2.4 Biochemical estimations**

32
33 Following spectral acquisition, each tissue was divided in two parts. One part was homogenized
34 in appropriate buffer and processed for protein estimation. Other part was homogenized in
35 alcohol/acetone solution and utilized for total lipid and phospholipid estimation. Estimation of
36 total protein, total lipid and phospholipid content was carried out on the same tissues to establish
37 a correlation between spectral features and biochemical composition.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2.4.1 Total protein estimation: Folin-Lowry assay, proposed by Oliver H. Lowry in 1951, one of the most commonly used methods of protein estimation was employed³⁶. This method is based on two chemical reactions. The first reaction is the reduction of copper ions under alkaline conditions, which forms a complex with peptide bonds (Biuret reaction). The second is the reduction of Folin-Ciocalteu reagent by the copper-peptide bond complex, which subsequently causes a color change of the solution. It gives the dark blue to purplish and can be measured at any wavelength between 650 nm and 750 nm with little loss of intensity. It is best to measure the color at 750 nm since it is more sensitive as very few other substances absorb light at this wavelength. Tumor and normal tissues were homogenized in appropriate buffer. A standard curve was plotted by employing varying concentrations of BSA. The procedure is as follows: One hundred μ l of either blank/ standard (5-40 μ g BSA solution)/ sample (tissue homogenate) were taken in test tubes. To this, 1 ml of freshly prepared CTC solution (0.8 N NaOH, 10% sodium dodecyl sulphate (SDS) in D/W) was added and the tubes were vortexed for thorough mixing. After incubation at RT for 10 min, 500 μ l of FC reagent (1:6 dilution) was added. The tubes were vortexed and incubated in the dark for 30 min at RT. All samples and standards were run in duplicates. The concentration of protein (expressed per mg of tissue weight) in the samples was determined from the standard curve.

2.4.2 Total lipid estimation: The total lipid content of the tissues was estimated using the protocol of Floch *et al.*³⁷. In this method first the tissue was homogenized in chloroform/methanol (2/1) mixture in a final volume 20 times to the volume of the tissue sample (*e.g.* 1g in 20 ml of solvent mixture). After dispersion, the whole mixture was agitated for 15-20 minutes in an orbital shaker at room temperature. The liquid phase of the homogenate was recovered after centrifugation at 1000 rpm for 15 minutes. This was followed by washing with 0.2 volumes (4 ml for 20 ml) of 0.9% sodium chloride (NaCl) solution. After vortexing the mixture was centrifuged at low speed (2000 rpm) to separate the two phases. The upper phase was removed by siphoning. The remaining solvent along with the interface was washed with methanol/water (1/1) solution without mixing the whole preparation. The lower chloroform phase containing lipids was evaporated under a nitrogen stream and lipid content was expressed per mg tissue weight.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2.4.3 Phospholipid estimation: Estimation of phospholipids was performed by the method of Rouser *et al.*³⁸. This method is based on the principle of converting the organic phosphorus to inorganic phosphorus, which on reaction with ammonium molybdate, forms phosphomolybdic acid. This in turn, on reduction with ascorbic acid, forms a stable color which can be read optically at 800 nm. Dried total lipid samples and standards (1 to 5 $\mu\text{g P/tube}$) were dissolved in 0.65 ml perchloric acid and placed in heated block for about 30 minutes or until the yellow color disappears. After cooling, 3.3 ml water, 0.5 ml of molybdate solution and 0.5 ml of ascorbic acid solution were added to the tubes and tubes were agitated on a vortex after each addition. The tubes were placed in a boiling water bath for 5 minutes and the absorbances of cooled samples (including the standards) were read at 800 nm using the spectrometer (U-2001, Hitachi, Japan). Amount of phospholipids were calculated using the standard curve and expressed in per mg of tissue weight.

3. Results and Discussion

3.1 Mean spectra

The mean spectra along with standard deviation of normal and tumor tissues are shown in Figure 1A and B, respectively. Architectural arrangements of different layers are considered as the hallmark of spectral profile. The spectral features observed in the present study corroborates with the profiles noted in our earlier reports¹⁹⁻³⁰. Origin of lipid rich features in normal tissues has been primarily attributed to the architectural arrangement of different layers. Under normal conditions, clear stratification between different layers like epithelium (superficial), lamina propria (sub epithelial connective tissue) and submucosa (deeper portion of connective tissue) can be seen. Biochemically, the lamina propria contains reticulin and collagen fibers, while the submucosa is rich in adipose tissue. This is supported by predominant lipid signatures e.g. ester bands (1744 cm^{-1}), strong δCH_2 bend (1440 cm^{-1}), two sharp features around amide III and a sharp peak around 1440 cm^{-1} seen in the mean normal spectrum. Therefore relatively weak and sharp band around 1650 cm^{-1} in normal tissues has been assigned to C=C modes of lipids. In case of tumors, there is a loss of architectural arrangement of the different layers, therefore content of different layers are mixed and lipid features are not seen. Additionally in case of malignancy, cells have large amounts of surface proteins, like receptor proteins, enzymes, antigens, and

1
2
3 antibodies, which may lead to a protein-dominated spectrum as indicated by broad amide III,
4 broadened δCH_2 , strong and broad features in the amide I region.
5
6

7 **3.2 Curve-Deconvolution**

8
9 In conventional or macro Raman spectroscopy, the spectra are acquired over a large probing area
10 (20-100 μm) and represent gross information e.g. spectra in the present study were acquired over
11 an area of 105 μm . It is also well known that a spectrum is an envelope of different bands arising
12 from various biochemical constituents for complex biological samples. For example amide III
13 region (1200-1400 cm^{-1}) of any biological sample can have mixture of bands arising from
14 disordered proteins, α -helix, β -sheet of proteins, collagen, lipids and DNA. By utilizing proper
15 data mining tools - e.g. spectral subtraction or multivariate analysis (principal component
16 analysis, linear discriminant analysis, etc.), correlation of Raman spectra with biochemical
17 components can be achieved. Curve deconvolution is one such method. The goal of curve
18 deconvolution is to mathematically create individual peaks from a spectrum that, when added
19 together, match the original data. Using an optimal fitting function, spectra are resolved into
20 individual components and peak parameters such as location (frequency), height (intensity),
21 FWHM and area under band can be obtained²²⁻²⁴. In this method second derivative calculation is
22 done first to identify the possible number of peaks existing in a data set/spectrum. The number of
23 distinct minima for the second derivative and their position gives a good indication about peak
24 number and location. It is followed by identifying optimum fitting functions *i.e.* Gaussian,
25 Lorentzian or mixed. In our analysis Gaussian function led to best fit. Spectra were interpolated
26 to specific ranges (δCH_2 and amide I region) and curve deconvolution utilizing Gaussian function
27 was performed (Figure 2 and 3). The spectra after curve deconvolution (FT), residual (R)
28 depicting differences between the original and fitted spectra, and 2nd derivative spectra (2D)
29 indicating exact peak positions were also generated.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Raman bands at 1430 cm^{-1} (CH_2 scissoring), 1443 cm^{-1} (CH_2 and CH_3 deformation of
47 lipids and triglycerides), 1453 cm^{-1} (C-H bending of lipids, amino acids side chains) and 1480
48 cm^{-1} (C=N stretching of nucleic acids) in normal and tumor spectrum were fitted in the δCH_2
49 region (1400-1500 cm^{-1}) (Figure 2A,B and Figure 3A,B). Four bands at 1620 cm^{-1} (Trp (IgG),
50 Phe, Tyr), 1660 cm^{-1} (amide I vibration mode of structural proteins, $\nu(\text{C}=\text{C})$ cis lipids, fatty
51 acids), 1680 cm^{-1} (amide I, β -sheet) and 1750 cm^{-1} (C=O esters of lipids and fatty acids) were
52
53
54
55
56
57
58
59
60

1
2
3 fitted in the amide I region ($1600\text{-}1800\text{ cm}^{-1}$) of normal spectrum (Figure 2C,D). Five bands at
4
5 1540 cm^{-1} (heme and aromatic hydrogens), 1590 cm^{-1} (C=N and C=C stretching in quinoid ring),
6
7 1628 cm^{-1} (amide C=O stretching for the β -form polypeptide films), 1655 cm^{-1} (amide I vibration
8
9 mode of structural proteins, $\nu(\text{C}=\text{C})$ cis lipids, fatty acids) and 1690 cm^{-1} (amide I disordered
10
11 structures, β -sheet) were fitted in the tumor spectrum in the $1500\text{-}1800\text{ cm}^{-1}$ range (Figure 3C,D).
12 The average intensity of the lipid band (1440 cm^{-1}) in normal and tumor tissues was 1.42 ± 0.25
13 and 0.43 ± 0.18 , respectively (Figure 4A and Table 1). This difference was found to be
14 statistically significant by unpaired student's t-test ($p < 0.0001$). The average intensity of the
15 protein band (1450 cm^{-1}) was high in tumors (1.46 ± 0.29) as compared to normal (0.51 ± 0.12)
16 (Figure 4B and Table 1). Again, this difference was found to be highly significant ($p < 0.0001$).
17 The average intensity associated with the other protein band (1660 cm^{-1}) in the amide I region
18 was also computed. Statistically significant difference (p value = 0.004) between normal
19 (0.89 ± 0.28) and tumor (1.12 ± 0.19) tissues (Figure 4C and Table 1) was observed. In order to
20 determine if the band intensity parameters can be explored for classification, scatter intensity
21 plots of lipid (1440 cm^{-1}) against protein bands (1450 cm^{-1} and 1660 cm^{-1}) were generated
22 (Figure 4D and 4E). Two separate clusters indicating higher intensity of lipid band (1440 cm^{-1})
23 were obtained in normal tissues as compared to tumor tissues. Similarly, the intensity of the
24 protein bands (1450 cm^{-1} and 1660 cm^{-1}) was high in case of tumors (Figure 4D and 4E).
25
26
27
28
29
30
31
32
33
34
35

36 3.3 Biochemical estimations

37
38 The presence of tumor in the body produces a number of deleterious effects such as anorexia,
39
40 nausea, impaired digestion and cachexia in the host which leads to variety of biochemical
41
42 differences among normal and malignant cells. Cancer cells show a variety of alterations on the
43
44 cell surface and also display disturbed arrangement of the cell membrane, as compared to their
45
46 normal counterparts. The alteration in membrane lipids is considered as an important aspect of
47
48 malignant transformation. In the next step, to verify if the spectral markers can serve as
49
50 biochemical markers, estimation of total lipid, total protein and phospholipid was performed
51
52 using the same tissues. The protein to lipid and phospholipid ratio was calculated. As shown in
53
54 Figure 5A and Table 1, protein to lipid ratio was high in case of tumors (2.15 ± 0.41) with respect
55
56 to normal tissues (0.72 ± 0.22). When unpaired student's t-test was performed, a statistically
57
58 significant difference ($p < 0.0001$) was observed. As can be seen from Figure 5B and Table 1,
59
60

1
2
3 protein to phospholipid ratio yielded similar and significant results *i.e.* high in tumors
4 (24.13±2.12) and low in normal (16.12±2.28).
5
6

7 **3.4 Correlation of curve-deconvolution and biochemical estimations**

8
9 Mean spectral profile of normal tissues indicates predominance of lipids while tumor spectra are
10 rich in proteins. These features corroborate the spectral profile noted in our earlier reports²¹⁻³⁰.
11 Curve-deconvolution procedures can help in resolving overlapping bands which can lead to
12 better interpretation and correlation of biochemical constituents. Similar to features observed in
13 the mean/average spectra, intensity associated with protein bands was high in case of tumors
14 (1.46±0.29 and 1.12±0.19) while that of lipid band was high in normal (1.42 ± 0.25), Table 1.
15 However, in view of variable Raman scattering cross-section it is also important to analyze
16 spectral features with respect to tissue biochemical composition to correlate spectral markers as
17 biochemical markers. As can be seen from Table 1, Corroborating mean spectral profile and
18 findings of curve-deconvolution analysis, biochemical estimation yielded similar results *i.e.*
19 protein to lipid ratio was high in case of tumors (2.15±0.41) and *vice versa* for normal (0.72±0.22).
20 Origin of these features in normal tissues is primarily attributed to the architectural arrangement
21 of different layers. In case of pathological conditions cells contain large amounts of surface
22 proteins, receptor proteins, enzymes, antigens and anti-bodies which might be responsible for the
23 protein dominated spectrum. In addition to the deleterious effects described earlier lipids are also
24 required for maintaining cell shape, signaling and various cell processes. Polyunsaturated fatty
25 acids are the major class of biomolecules susceptible to oxidative damage by reactive oxygen
26 species generated by tobacco exposure. This could be one of the reasons for the decreased
27 amounts of lipids in cancerous conditions, as suggested by Raman spectra and confirmed by
28 biochemical estimation. A decrease in the phospholipid concentration can be attributed to
29 dysfunction of the cell membrane in malignancy leading to an increase in phospholipid
30 degradation.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **4. Conclusions**

48 Raman spectra are sensitive towards histological or biochemical variations associated with
49 disease onset. Histopathological and Raman spectra correlation are well documented. In the
50 present study biochemical variations *viz a viz* Raman spectra have been investigated. Gross
51 spectral features, intensity of curve-resolved protein/lipid bands and biochemical estimation
52
53
54
55
56
57
58
59
60

1
2
3 suggest that the lipid to protein ratio is high in normal tissue and *vice versa* in tumors. Overall
4 findings of this study indicate that, spectral features are the true representative of underlying
5 biochemical make-up of a tissue and supports utility of protein to lipid ratio as a prospective
6 spectral and biochemical marker for oral cancer diagnosis.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

This work, carried out under Project No. BT/PRI11282/MED/32/83/2008 Department of Biotechnology, Government of India. The authors would like to acknowledge the help received from Mrs. Arti R. Hole in histopathological analysis of tissues. The contribution of Dr. Gaurav Kumar and Dr. G.B. Maru in biochemical analysis is also acknowledged. Editorial makeover of the manuscript by Dr. A. Bagwe, SCOPE Cell, ACTREC and Ms. Aditi Sahu is gratefully acknowledged.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; (2012)
2. J Ferlay, HR Shin, F. Bray, D. Forman, C. Mathers, D. Parkin, *Int J Cancer*. 127, 2893–2917 (2008).
3. D.M. Saman, *Head & Neck Oncology*, 4,1-7 (2012).
4. R Dikshit, PC Gupta , C Ramasundarahettige , V Gajalakshmi, L Aleksandrowicz , R Badwe, R Kumar, S Roy , W Suraweera , F Bray , Mallath M, PK Singh, DN Sinha , Shet AS, Gelband H, Jha P, *Lancet*. 379,1807-1816 (2012).
5. P. Boffetta, S. Hecht, N. Gray, P. Gupta and K. Straif, *The Lancet Oncology*, 2008, 9, 667–75.
6. B Mathew, R Sankaranarayanan, KB Sunil kumar, P Pisani, M Krishnan Nair, *Br J Cancer*,76, 390-394 (1997).
7. L.M. Abbey, G.E. Kaugars, J.C. Gunsolley, J.C. Burns, D.G. Page, J.A. Svirsky, E. Eisenberg, D.J. Krutchkoff, M. Cushing, *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, 80, 188-191(1995).
8. D.C. De Veld, M.J. Witjes, H.J. Sterenberg, J.L. Roodenburg, *Oral Oncol*, 4, 117-131(2005).
9. J.G. Wu, Y.Z Xu, C.W. Sun, R.D. Soloway, D.F. Xu, Q.G. Wu, K.H. Sun, S.F. Weng, G.X. Xu, *Biopolymers*, 48,167-175 (2005).
10. P. Crow, B. Barrass, C. Kendall, M. Hart-Prieto, M. Wright, R. Persad, N. Stone *Br J Cancer* 92, 2166-2170 (2005).
11. G. Shetty, C. Kendall, N. Shepherd, N. Stone, H. Barr, *Br J Cancer* 94, 1460-1464 (2006).
12. S. Duraipandian, M. Sylvest Bergholt, W. Zheng, K. Yu Ho, M. Teh, K. Guan Yeoh, J. Bok Yan So, A. Shabbir , Z. Huang, *J Biomed Opt* 17, 081418 (2012).
13. Z. Huang, Z., S. K. Teh, W. Zheng, K. Lin, K. Y. Ho, M. The, K. G. Yeoh, *Biosens Bioelectron* 26,383-389 (2010).
14. E.M. Kanter, E. Vargis, S. Majumder, M. D. Keller, E. Woeste, G. G. Rao, A. Mahadevan-Jansen , *J Biophotonics* 2, 81-90 (2009).

15. S. Koljenovic, T. C. Bakker Schut, R. Wolthuis, B. de Jong, L. Santos, P. J. Caspers, J. M. Kros, G. J. Puppels, *J Biomed Opt* 10,031116 (2005).
16. M.D. Morris, G. S. Mandair(2011), *Clin Orthop Relat Res*, 469, 2160-2169 (2011).
17. J. Popp, C. Krafft T. Mayerhöfer, *Optik & Photonik* 6,24-28 (2011).
18. T. Meyer, N. Bergner, C. Bielecki, C. Krafft, D. Akimov, B. F. M. Romeike, R. Reichart, R. Kalff, B. Dietzek, J. Popp, *J Biomed Opt* 16,021113-021110 (2011).
19. K. Venkatakrishna, J. Kurien, K.M. Pai, C. Murali Krishna, G. Ullas, V.B. Kartha, *Curr. Sci*, 80, 101-05(2001).
20. C.M. Krishna, G.D. Sockalingum, J. Kurien, L. Rao, L. Venteo, M. Pluot, M. Manfait, V.B. Kartha, *Appl Spectrosc*,58, 1128-1135 (2004).
21. R. Malini, K. Venkatakrishna, J. Kurien, K. M. Pai, L. Rao, V. B. Kartha, and C. M. Krishna, *Biopolymers*, 8, 179-193 (2006).
22. K. Guze, M. Short, S. Sonis, N. Karimbux, J. Chan, H.Zeng, *J Biomed Opt*, 140, (2009).
23. H. Zhiwei , K.T. Seng, Z. Wei, M. Jianhua, L. S Kan, Xiaozhuo, Y.H. Khek, T. Ming, G.Y. Khay, *Opt Lett*, 34, 758-760 (2009).
24. A.T. Harris , A. Rennie , H. Waqar-Uddin , S.R. Wheatley , S.K. Ghosh , D.P. Martin-Hirsch, S.E. Fisher , A.S. High , J. Kirkham , T. Upile, *Head & Neck Oncology*, 2, 1-6(2010).
25. SP Singh, A. Deshmukh, P Chaturvedi, CM Krishna, *J Cancer Res Ther.* 8, 126-132 (2012).
26. SP Singh, A. Deshmukh, P. Chaturvedi, CM Krishna, *Proc. of SPIE*, 8219, K1-K6(2012).
27. SP Singh, A. Deshmukh, P Chaturvedi, CM Krishna, *J Biomed Opt*, 17,21-29(2012).
28. SP Singh, Aditi Sahu, A. Deshmukh, P. Chaturvedi, CM Krishna, *Analyst*,138, 4175-4182 (2013).
29. A Sahu, A. Deshmukh. AD Ghanate, SP Singh, P. Chaturvedi, CM Krishna, *Technol Cancer Res Treat*, 1, 529-541(2012).
30. A. Deshmukh, SP Singh, P Chaturvedi and C M Krishna, *J. Biomed. Opt.*,16, 127004-10 (2011).
31. A. S. Haka, KE. Safer-Peltier, M Fitzmaurice, J Crowe, RR. Dasari, and MS Feld, *PNAS* 102, 12371-12376 (2005).
32. MV Chowdary , Kalyan Kumar K, S Mathew , L Rao , CM Krishna , Kurien J, *Biopolymers*.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

9, 539-546(2009).

33. MV Chowdary , KK Mahato , Kumar KK, S Mathew , L Rao , CM Krishna, J. Kurien,
Photomed Laser Surg, 27, 241-252 (2009).
34. PLS plus/IQ User's Guide; Galactic Industries Corporation, 1999
35. D. W. Marquardt, *J. Soc. Ind. Appl. Math.*, 11, 431-441 (1963).
36. OH Lowry , NJ Rosebrough , AL Farr , RJ Randall , *J Biol Chem*, 193, 265-275(1951).
37. Folch J, M Lees, GH Sloane, *J Biol Chem*, 226, 497–509 1957).
38. Rouser G, Fkeischer S, Yamamoto A, *Lipids*. 5, 494-496(1970).

Table 1: Raman intensity and Biochemical estimation of protein, lipids and phospholipids of normal and tumor tissues

	Normal (n=20)		Tumor (n=20)	
	Raman intensity	Biochemical estimation	Raman intensity	Biochemical estimation
Protein	0.51±0.12 (1450 cm ⁻¹) 0.89±0.28 (1660 cm ⁻¹)	0.28±0.08 (Protein / Lipid) (0.72±0.22)	1.46±0.29 (1450 cm ⁻¹) 1.12±0.19 (1660 cm ⁻¹)	0.62±0.12 (Protein / Lipid) (2.15±0.41)
Lipid	1.42 ± 0.25 (1440 cm ⁻¹)	0.37±0.45 (Protein / Lipid) (0.72±0.22)	0.43±0.18 (1440 cm ⁻¹)	0.28±0.59 (Protein / Lipid) (2.15±0.41)
Phospholipid	NA	0.016±0.11 (Protein / Phospholipid) (16.12±2.28)	NA	0.025±0.28 (Protein/Phospholipid) (24.13±2.12)

Figure legends


Figure 1: Mean / average spectra along with standard deviation of normal (A) and tumor (B) oral biopsies. (Solid line: mean spectra; dotted line: positive standard deviation; broken line: negative standard deviation)

Figure 2: Curve deconvolution of normal spectra in CH₂ region (A-B) and amide I region (C-D). (2D – 2nd Derivative; FT- Fitted trace; R- Residual)


Figure 3: Curve deconvolution of tumor spectra in CH₂ region (A-B) and amide I region (C-D). (2D – 2nd Derivative; FT- Fitted trace; R- Residual)

Figure 4: Average intensity of Raman bands in normal (empty bar) and tumor (shaded bar). (A) lipid band (1440 cm⁻¹); (B) Protein band (1450 cm⁻¹); (C) Protein band (1660 cm⁻¹); (D) Scatter intensity plot of lipid bands (1440 cm⁻¹) and protein (1450 cm⁻¹) (E) Scatter intensity plot between lipid (1440 cm⁻¹) and protein band (1660 cm⁻¹) [Δ -Normal , \bullet -Tumor].


Figure 5: Biochemical estimation of protein and lipids in normal (empty bar) and tumor (shaded bar). (A) Ratio of total protein to total lipid; (B) Ratio of total protein to phospholipid.




Mean / average spectra along with standard deviation of normal (A) and tumor (B) oral biopsies. (Solid line: mean spectra; dotted line: positive standard deviation; broken line: negative standard deviation)
285x338mm (300 x 300 DPI)



Curve deconvolution of normal spectra in CH₂ region (A-B) and amide I region (C-D). (2D – 2nd Derivative; FT- Fitted trace; R- Residual)
172x124mm (300 x 300 DPI)




Curve deconvolution of tumor spectra in CH₂ region (A-B) and amide I region (C-D). (2D – 2nd Derivative; FT- Fitted trace; R- Residual)
163x114mm (300 x 300 DPI)



Average intensity of Raman bands in normal (empty bar) and tumor (shaded bar).
 (A) lipid band (1440 cm⁻¹); (B) Protein band (1450 cm⁻¹); (C) Protein band (1660 cm⁻¹); (D) Scatter intensity plot of lipid bands (1440 cm⁻¹) and protein (1450 cm⁻¹) (E) Scatter intensity plot between lipid (1440 cm⁻¹) and protein band (1660 cm⁻¹) [-Normal , - Tumor].

162x105mm (300 x 300 DPI)



Biochemical estimation of protein and lipids in normal (empty bar) and tumor (shaded bar). (A) Ratio of total protein to total lipid; (B) Ratio of total protein to phospholipid.
97x38mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60